Comparing two conditioning regimens for pediatric leukemia treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares the effects of two conditioning regimens, Total Body Irradiation (TBI) and Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI), on pediatric patients with acute lymphoblastic leukemia (ALL) undergoing matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT). The goal is to determine which regimen more effectively eliminates leukemia cells while minimizing damage to normal tissues and reducing transplant-related complications. Participants aged 1-17 years in remission will be randomly assigned to receive either TBI or TMLI, with the aim of improving survival outcomes and quality of life for these young patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Informed Consent: Participants or guardians must voluntarily sign a written informed consent form.
2. Age and Gender: Participants should be male or female, aged 1-17 years, inclusive.
3. Diagnosis: Participants must be diagnosed with acute lymphoblastic leukemia (ALL) according to World Health Organization (WHO) criteria, and the diagnosis must apply to pediatrics aged 1-17 years.
4. Remission Status: The participant's leukemia must be in hematologic remission (complete remission, CR) prior to transplantation.
5. Donor Availability: There must be a suitable matched sibling donoravailable, and the participant must consent to undergo MSD hematopoietic stem cell transplantation (MSD-HSCT).
6. Karnofsky Performance Status: The participant must have a Karnofsky score of 70 or higher, indicating that they are capable of caring for themselves and carrying out normal activities. Additionally, they must not have significant organ dysfunction, defined by the following:

   * Cardiac Function: New York Heart Association (NYHA) classification of class II or lower.
   * Liver Function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be no more than 2.5 times the upper limit of normal. Bilirubin levels should be no more than 2 times the upper limit of normal.
   * Renal Function: Serum creatinine levels should be no more than 1.5 times the upper limit of normal, or the creatinine clearance rate should be at least 60 ml/min. o Pulmonary Function: Participants should not experience significant dyspnea, should not require oxygen therapy, should not have interstitial lung disease, and should not have any active pulmonary infections.

Exclusion Criteria: To be eligible for inclusion in the study, participants must not meet any of the following criteria:

1\. The patient has not achieved hematologic remission before transplantation. 2. The patient has chosen a non-MSD donor.

3\. The patient has severe cardiac, hepatic, renal, or pulmonary diseases that make them unable to tolerate the conditioning regimen.

4\. The patient has an active or refractory infection, or other life-threatening complications.

5\. The patient has a history of other malignant tumors, psychiatric disorders, or HIV infection.

6\. The patients or guardians refuses to sign the informed consent form, is unwilling to comply with clinical follow-up required by the study, or does not consent to the use of their data to support future research, project presentations, and clinical practices.

7\. The investigator deems the patient unsuitable for participation in the study for any other reason.

Where it's running

• The First Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Zhilei Bian, PhD.
• Email: bianzhilei@sina.com
• Phone: +86037166862278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival

  This study tests how children in China with Philadelphia chromosome–positive ALL are diagnosed, treated, and how long they survive in real-world practice.

  Recruiting The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07813208

• Finding the right dose of MB-CART2219.1 CAR‑T (targets CD19 and CD22) for relapsed B‑cell cancers

  This trial will test MB‑CART2219.1, a CAR‑T cell therapy that targets CD19 and CD22, in adults and children with relapsed or refractory B‑cell cancers to find a safe dose.

  Recruiting Phase 1 University Hospital Tuebingen · Tübingen, Baden-Wurttemberg and 1 other locations · NCT07108868

• Impact of massage therapy on sleep in young cancer patients

  This study is testing whether personalized massage therapy can help young cancer patients in the hospital sleep better and feel less tired, anxious, and in pain during their treatment.

  Recruiting Children's Hospital of Philadelphia · Washington D.C., District of Columbia and 1 other locations · NCT06892158

• CAR-T cell therapy for children with relapsed leukemia or lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help children with relapsed leukemia or lymphoma feel better and improve their chances of recovery.

  Recruiting Hong Kong Children's Hospital · Hong Kong · NCT06866873

• Using virtual reality to ease lumbar punctures in children with leukemia

  This study is testing whether using virtual reality can help kids with leukemia feel less pain and anxiety during lumbar punctures, so they might not need general anesthesia.

  Recruiting Children's National Research Institute · Washington D.C., District of Columbia · NCT06722638

• Comparing two conditioning regimens for pediatric leukemia treatment

  This study is testing which of two treatment plans, Total Body Irradiation or Total Marrow Irradiation, works better for kids with leukemia getting a stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT06559345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.